Although ZBTB38 has not been previously investigated in GC, it has been characterized as a tumor suppressor in prostate cancer (Ding et al., 2021; de Dieuleveult et al., 2020) and conversely, as an oncogene in bladder cancer (Jing et al., 2019). Here, ZBTB38 is linked to prostate carcinoma.